Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Imugene ( (AU:IMU) ).
Imugene Limited has released a report detailing the top holders of its securities, with HSBC Custody Nominees (Australia) Limited holding the largest share at 15.61%. This report provides insights into the company’s shareholder structure, which could influence investor confidence and market perception.
The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited operates in the biotechnology industry, focusing on the development of novel therapies for cancer treatment. The company is primarily engaged in advancing immuno-oncology therapies, aiming to enhance the body’s immune response against tumors.
Average Trading Volume: 1,690,173
Technical Sentiment Signal: Sell
Current Market Cap: A$76.45M
For detailed information about IMU stock, go to TipRanks’ Stock Analysis page.